Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
Clin Liver Dis. 2012 May;16(2):397-419. doi: 10.1016/j.cld.2012.03.005.
As the hepatic manifestation of the metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of asymptomatic liver enzyme elevations in Western nations. Although it is easy to diagnose NAFLD, a liver biopsy is currently required to diagnose nonalcoholic steatohepatitis (NASH). Patients with NASH are those at greatest risk of progression to cirrhosis and, thus, treatment efforts are targeted to these individuals. Although currently there are no FDA-approved treatments for NASH, a multidisciplinary approach that addresses comorbid conditions and promotes modest weight loss comprises the backbone of therapy.
作为代谢综合征的肝脏表现，非酒精性脂肪性肝病（NAFLD）已成为西方国家无症状肝酶升高的最常见原因。尽管 NAFLD 易于诊断，但目前仍需要肝活检来诊断非酒精性脂肪性肝炎（NASH）。NASH 患者进展为肝硬化的风险最大，因此治疗重点针对这些患者。虽然目前尚无 FDA 批准的 NASH 治疗方法，但针对合并症和促进适度体重减轻的多学科方法构成了治疗的基础。
